Evidence map›Paper›PMID 33237933›Full record

ArticlePLoS neglected tropical diseases2020

Mass administration of medicines in changing contexts: Acceptability, adaptability and community directed approaches in Kaduna and Ogun States, Nigeria.

Oluwatosin Adekeye, Kim Ozano, Ruth Dixon, Elisabeth Osim Elhassan, Luret Lar, Elena Schmidt, Sunday Isiyaku, Okefu Okoko, Rachael Thomson, Sally Theobald and 1 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Factors Associated with the Acceptability of Mass Drug Administration for Filariasis: A Systematic Review.International journal of environmental research and public health · 2022
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Oluwatosin AdekeyeSightsavers, Nigeria Country Office, Kaduna State, Nigeria.ORCID 0000-0003-0347-3770
Kim OzanoDepartment of International Public Health, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom.
Ruth DixonSightsavers, Research Team, Haywards Heath, United Kingdom.
Elisabeth Osim ElhassanSightsavers, Nigeria Country Office, Kaduna State, Nigeria.ORCID 0000-0002-6988-7194
Luret LarSightsavers, Nigeria Country Office, Kaduna State, Nigeria.
Elena SchmidtSightsavers, Research Team, Haywards Heath, United Kingdom.
Sunday IsiyakuSightsavers, Nigeria Country Office, Kaduna State, Nigeria.
Okefu OkokoNeglected Tropical Disease Programme, Federal Ministry of Health, Government of Nigeria, Abuja, Nigeria.ORCID 0000-0001-7496-4118
Rachael ThomsonDepartment of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom.
Sally TheobaldDepartment of International Public Health, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom.
Laura DeanDepartment of International Public Health, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nigeria has the highest burden of NTDs in sub-Saharan Africa. Commitments to reach the control and elimination of many Neglected Tropical Diseases (NTDs), particularly those amenable to preventive chemotherapy (onchocerciasis, schistosomiasis, soil transmitted helminths, lymphatic filariasis and trachoma) by 2020 are detailed in the London declaration. Strategies to reach targets build on existing approaches, one of which is the use of community directed intervention (CDI) methods to deliver the mass administration of medicines (MAM). However, treatment using this approach has been inconsistent and there are questions about the acceptability and adaptability of these interventions during periods of programmatic, social, and political change. This paper explores the current strengths and weaknesses of CDI approaches in MAM delivery. We consider the acceptability and adaptability of existing MAM approaches to ensure equity in access to essential treatments. Using qualitative methods, we explore implementer perspectives of MAM delivery. We purposively selected programme implementers to ensure good programmatic knowledge and representation from the different levels of health governance in Nigeria. Data collection took place across two States (Kaduna and Ogun). Our results indicate that CDI approaches have underpinned many historic successes in NTD programme acceptance in Nigeria, specifically in Kaduna and Ogun State. However, our results also show that in some contexts, factors that underpin the success of CDI have become disrupted presenting new challenges for programme implementers. Capturing the tacit knowledge of health implementers at varying levels of the health system, we present the current and changing context of MAM delivery in Kaduna and Ogun States and consolidate a platform of evidence to guide future programme delivery and research studies. We situate our findings within the broader NTD literature, specifically, in identifying how our findings align to existing reviews focused on factors that shape individual acceptance of MAM.

Indexed as

Antiprotozoal AgentsCommunity Health ServicesElephantiasis, FilarialHelminthiasisHumansMass Drug AdministrationNeglected DiseasesNigeriaOnchocerciasisSchistosomiasisTrachomaTropical MedicineAntiprotozoal Agents

Identifiers

PMID33237933
PMCPMC7725376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.